Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy
← catalyst calendarSponsored by Neurocrine Biosciences (industry) · NBIX — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
86actual
Sites
38
Countries
Argentina, Belgium, Brazil +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-04-15 | actual | When the study began enrolling |
| Primary completion | 2025-10-16 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-03-31 | actual | The whole study's end, after follow-up |
| First posted | 2022-01-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Dyskinesia
- Cerebral Palsy
Interventions
- Drug: Placebo
- Drug: Valbenazine — also filed as NBI-98854
Primary outcome
what the primary-completion date above is the date OFChange in the Total Maximal Chorea (TMC) Score of the Unified Huntington Disease Rating Scale (UHDRS) from Baseline to the Average of the Week 12 and Week 14 assessments
measured Baseline, Week 12 and Week 14
Permalink · NBIX's whole pipeline · Catalyst calendar · Every registered study · What changed